Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated Vaccine.
COVID-19
DNA vaccine
RBD
SARS-CoV-2
inactivated vaccine
variants
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
10 Jun 2022
10 Jun 2022
Historique:
received:
12
05
2022
revised:
02
06
2022
accepted:
08
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Objective: We constructed two DNA vaccines containing the receptor-binding domain (RBD) genes of multiple SARS-CoV-2 variants and used them in combination with inactivated vaccines in a variety of different protocols to explore potential novel immunization strategies against SARS-CoV-2 variants. Methods: Two DNA vaccine candidates with different signal peptides (namely, secreted and membrane signal peptides) and RBD protein genes of different SARS-CoV-2 strains (Wuhan-Hu-1, B.1.351, B.1.617.2, C.37) were used. Four different combinations of DNA and inactivated vaccines were tested, namely, Group A: three doses of DNA vaccine; B: three doses of DNA vaccine and one dose of inactivated vaccine; C: two doses of inactivated vaccine and one dose of DNA vaccine; and D: coadministration of DNA and inactivated vaccines in two doses. Subgroups were grouped according to the signal peptide used (subgroup 1 contained secreted signal peptides, and subgroup 2 contained membrane signal peptides). The in vitro expression of the DNA vaccines, the humoral and cellular immunity responses of the immunized mice, the immune cell population changes in local lymph nodes, and proinflammatory cytokine levels in serum samples were evaluated. Results: The antibody responses and cellular immunity in Group A were weak for all SARS-CoV-2 strains; for Group B, there was a great enhancement of neutralizing antibody (Nab) titers against the B.1.617.2 variant strain. Group C showed a significant increase in antibody responses (NAb titers against the Wuhan-Hu-1 strain were 768 and 1154 for Group C1 and Group C2, respectively, versus 576) and cellular immune responses, especially for variant B.1.617.2 (3240 (p < 0.001) and 2430 (p < 0.05) for Group C1 and Group C2, versus 450); Group D showed an improvement in immunogenicity. Group C induced higher levels of multiple cytokines. Conclusion: The DNA vaccine candidates we constructed, administered as boosters, could enhance the humoral and cellular immune responses of inactivated vaccines against COVID-19, especially for B.1.617.2.
Identifiants
pubmed: 35746536
pii: vaccines10060929
doi: 10.3390/vaccines10060929
pmc: PMC9228235
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : People's Government of Yunnan Province
ID : 202102AA310043
Organisme : People's Government of Yunnan Province
ID : 202101AS070053
Références
Lancet. 2022 Feb 5;399(10324):521-529
pubmed: 35074136
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
PLoS One. 2022 Jan 21;17(1):e0260733
pubmed: 35061702
Front Immunol. 2018 Jul 09;9:1568
pubmed: 30038621
J Med Virol. 2020 May;92(5):501-511
pubmed: 32027035
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
J Zhejiang Univ Sci B. 2020 May;21(5):343-360
pubmed: 32425000
Vaccine. 2017 Oct 9;35(42):5559-5567
pubmed: 28882437
Virusdisease. 2022 Mar;33(1):1-22
pubmed: 35127995
Clin Microbiol Infect. 2022 Feb;28(2):202-221
pubmed: 34715347
EClinicalMedicine. 2021 Aug;38:101020
pubmed: 34308319
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Infect Dis Rep. 2021 Oct 28;13(4):924-929
pubmed: 34842753
JAMA. 2020 Sep 8;324(10):951-960
pubmed: 32789505
PLoS One. 2022 Feb 2;17(2):e0263468
pubmed: 35108321
Lancet Infect Dis. 2021 Aug;21(8):1107-1119
pubmed: 33773111
Cell. 2020 May 14;181(4):914-921.e10
pubmed: 32330414
EClinicalMedicine. 2021 Jan;31:100689
pubmed: 33392485
Vet Clin North Am Small Anim Pract. 2018 Mar;48(2):231-241
pubmed: 29217317
Vaccine. 2016 Jan 20;34(4):413-423
pubmed: 26691569
EBioMedicine. 2022 Jan;75:103761
pubmed: 34929493
Front Public Health. 2021 Nov 30;9:775224
pubmed: 34917580
Front Immunol. 2022 Jan 03;12:809244
pubmed: 35046961
Lancet Infect Dis. 2021 Jun;21(6):803-812
pubmed: 33548194
Curr Opin Immunol. 2009 Jun;21(3):346-51
pubmed: 19500964
Euro Surveill. 2021 Oct;26(41):
pubmed: 34651577
J Virol. 2021 Nov 9;95(23):e0131321
pubmed: 34549975
Lancet. 2020 Aug 15;396(10249):479-488
pubmed: 32702299
Lancet. 2021 Feb 20;397(10275):682-694
pubmed: 33524311
Lancet Infect Dis. 2021 Jan;21(1):39-51
pubmed: 33069281
Vaccine. 2021 May 12;39(20):2746-2754
pubmed: 33875266
Drug Saf. 2021 Dec;44(12):1247-1269
pubmed: 34739716
JAMA Intern Med. 2022 Feb 1;182(2):165-171
pubmed: 34928302
Cell Res. 2020 Oct;30(10):932-935
pubmed: 32759966
Nat Commun. 2020 May 20;11(1):2601
pubmed: 32433465
Hong Kong Med J. 2021 Oct;27(5):380-383
pubmed: 34657837
Microbiol Aust. 2020 Mar 17;:MA20013
pubmed: 32226946
Int J Biol Macromol. 2021 Oct 1;188:740-750
pubmed: 34403674
PLoS Pathog. 2022 Jan 12;18(1):e1010242
pubmed: 35020754
Vaccine. 2018 Apr 25;36(18):2394-2402
pubmed: 29602705
J Biomed Biotechnol. 2010;2010:174378
pubmed: 20368780
Clin Microbiol Infect. 2022 Mar;28(3):410-418
pubmed: 34715346
Life Sci. 2020 Nov 1;260:118400
pubmed: 32918975
J Med Virol. 2022 Jan;94(1):399-403
pubmed: 34460119
Braz J Med Biol Res. 2012 Dec;45(12):1102-11
pubmed: 22948379
Wien Klin Wochenschr. 2021 Sep;133(17-18):931-941
pubmed: 34378087
Mol Ther Methods Clin Dev. 2021 Dec 10;23:108-118
pubmed: 34462721
Lancet Infect Dis. 2021 Oct;21(10):1383-1394
pubmed: 33887208
Ther Adv Infect Dis. 2021 Jun 18;8:20499361211024372
pubmed: 34211709
Front Immunol. 2021 Nov 09;12:747830
pubmed: 34858404
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Front Immunol. 2020 Nov 06;11:589833
pubmed: 33240278
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
Vaccine. 2021 Jul 5;39(30):4108-4116
pubmed: 34120764
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Ann Intern Med. 2022 Feb;175(2):226-233
pubmed: 34807716